Cargando…
Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations
AIM: To evaluate the factors influencing suspected hypersensitivity and adverse systemic reactions after Shuxuening injection and to provide innovative ideas and methods for the reevaluation of post-marketing safety of Shuxuening. METHODS: This study used a prospective, nested case–control study des...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896674/ https://www.ncbi.nlm.nih.gov/pubmed/29670332 http://dx.doi.org/10.2147/DDDT.S156000 |
_version_ | 1783313859582361600 |
---|---|
author | Wang, Can Shi, Qing-ping Ding, Feng Jiang, Xiao-dong Tang, Wei Yu, Mei-Ling Zhu, Jian-Hua |
author_facet | Wang, Can Shi, Qing-ping Ding, Feng Jiang, Xiao-dong Tang, Wei Yu, Mei-Ling Zhu, Jian-Hua |
author_sort | Wang, Can |
collection | PubMed |
description | AIM: To evaluate the factors influencing suspected hypersensitivity and adverse systemic reactions after Shuxuening injection and to provide innovative ideas and methods for the reevaluation of post-marketing safety of Shuxuening. METHODS: This study used a prospective, nested case–control study design, combined with a prescription sequence analysis design method. It classified patients who exhibited trigger signals after administration of Shuxuening injection as suspected allergic patients and made comparisons with patients who did not report adverse effects to calculate the correlation between relevant risk factors and suspected allergic reactions. Randomized controlled studies and cohort studies of the adverse drug reaction (ADR) of Shuxuening were performed using a computer database. Data retrieval was carried out by the foundation governing the individual database. Meta-analysis was performed by using R3.2.3 software to evaluate the ADRs of Shuxuening. RESULTS: The results of real-world study showed that administration of Shuxuening in combination with potassium aspartate and magnesium, atorvastatin calcium, Shengmai injection, pantoprazole sodium, or high-dose medication was a risk factor for suspected allergic reactions. Meta-analysis showed that the incidence of adverse events was 5.84% (95% CI 0.0499; 0.0674), and serious adverse reaction rate was 4.36% (95% CI 0.0188; 0.0760) when Shuxuening was used in combination with these drugs. The incidence of allergic reaction was also influenced by the vehicle, duration of treatment, single dose, and indicated vs off-label use. CONCLUSION: Risk factors for adverse reaction following the use of Shuxuening injection in patients are associated with a single dose, vehicle, type of disease, and combination with potassium aspartate, atorvastatin calcium, Shengmai injection, injection with pantoprazole sodium, and other drugs. Physicians should be careful to follow guidelines when administering this drug. We further propose that the unique methodology used in this study may be useful for reevaluation of the safety of other traditional Chinese medicines. |
format | Online Article Text |
id | pubmed-5896674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-58966742018-04-18 Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations Wang, Can Shi, Qing-ping Ding, Feng Jiang, Xiao-dong Tang, Wei Yu, Mei-Ling Zhu, Jian-Hua Drug Des Devel Ther Original Research AIM: To evaluate the factors influencing suspected hypersensitivity and adverse systemic reactions after Shuxuening injection and to provide innovative ideas and methods for the reevaluation of post-marketing safety of Shuxuening. METHODS: This study used a prospective, nested case–control study design, combined with a prescription sequence analysis design method. It classified patients who exhibited trigger signals after administration of Shuxuening injection as suspected allergic patients and made comparisons with patients who did not report adverse effects to calculate the correlation between relevant risk factors and suspected allergic reactions. Randomized controlled studies and cohort studies of the adverse drug reaction (ADR) of Shuxuening were performed using a computer database. Data retrieval was carried out by the foundation governing the individual database. Meta-analysis was performed by using R3.2.3 software to evaluate the ADRs of Shuxuening. RESULTS: The results of real-world study showed that administration of Shuxuening in combination with potassium aspartate and magnesium, atorvastatin calcium, Shengmai injection, pantoprazole sodium, or high-dose medication was a risk factor for suspected allergic reactions. Meta-analysis showed that the incidence of adverse events was 5.84% (95% CI 0.0499; 0.0674), and serious adverse reaction rate was 4.36% (95% CI 0.0188; 0.0760) when Shuxuening was used in combination with these drugs. The incidence of allergic reaction was also influenced by the vehicle, duration of treatment, single dose, and indicated vs off-label use. CONCLUSION: Risk factors for adverse reaction following the use of Shuxuening injection in patients are associated with a single dose, vehicle, type of disease, and combination with potassium aspartate, atorvastatin calcium, Shengmai injection, injection with pantoprazole sodium, and other drugs. Physicians should be careful to follow guidelines when administering this drug. We further propose that the unique methodology used in this study may be useful for reevaluation of the safety of other traditional Chinese medicines. Dove Medical Press 2018-04-05 /pmc/articles/PMC5896674/ /pubmed/29670332 http://dx.doi.org/10.2147/DDDT.S156000 Text en © 2018 Wang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Wang, Can Shi, Qing-ping Ding, Feng Jiang, Xiao-dong Tang, Wei Yu, Mei-Ling Zhu, Jian-Hua Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations |
title | Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations |
title_full | Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations |
title_fullStr | Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations |
title_full_unstemmed | Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations |
title_short | Reevaluation of the post-marketing safety of Shuxuening injection based on real-world and evidence-based evaluations |
title_sort | reevaluation of the post-marketing safety of shuxuening injection based on real-world and evidence-based evaluations |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896674/ https://www.ncbi.nlm.nih.gov/pubmed/29670332 http://dx.doi.org/10.2147/DDDT.S156000 |
work_keys_str_mv | AT wangcan reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations AT shiqingping reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations AT dingfeng reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations AT jiangxiaodong reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations AT tangwei reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations AT yumeiling reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations AT zhujianhua reevaluationofthepostmarketingsafetyofshuxueninginjectionbasedonrealworldandevidencebasedevaluations |